BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 16189177)

  • 1. Different expression of catecholamine transporters in phaeochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2.
    Huynh TT; Pacak K; Brouwers FM; Abu-Asab MS; Worrell RA; Walther MM; Elkahloun AG; Goldstein DS; Cleary S; Eisenhofer G
    Eur J Endocrinol; 2005 Oct; 153(4):551-63. PubMed ID: 16189177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chromogranin a expression in phaeochromocytomas associated with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2.
    Cleary S; Phillips JK; Huynh TT; Pacak K; Fliedner S; Elkahloun AG; Munson P; Worrell RA; Eisenhofer G
    Horm Metab Res; 2007 Dec; 39(12):876-83. PubMed ID: 18046660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuropeptide Y expression in phaeochromocytomas: relative absence in tumours from patients with von Hippel-Lindau syndrome.
    Cleary S; Phillips JK; Huynh TT; Pacak K; Elkahloun AG; Barb J; Worrell RA; Goldstein DS; Eisenhofer G
    J Endocrinol; 2007 May; 193(2):225-33. PubMed ID: 17470513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes.
    Eisenhofer G; Walther MM; Huynh TT; Li ST; Bornstein SR; Vortmeyer A; Mannelli M; Goldstein DS; Linehan WM; Lenders JW; Pacak K
    J Clin Endocrinol Metab; 2001 May; 86(5):1999-2008. PubMed ID: 11344198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteomic profiling of von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 pheochromocytomas reveals different expression of chromogranin B.
    Brouwers FM; Gläsker S; Nave AF; Vortmeyer AO; Lubensky I; Huang S; Abu-Asab MS; Eisenhofer G; Weil RJ; Park DM; Linehan WM; Pacak K; Zhuang Z
    Endocr Relat Cancer; 2007 Jun; 14(2):463-71. PubMed ID: 17639059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters.
    van Berkel A; Rao JU; Lenders JW; Pellegata NS; Kusters B; Piscaer I; Hermus AR; Plantinga TS; Langenhuijsen JF; Vriens D; Janssen MJ; Gotthardt M; Timmers HJ
    J Nucl Med; 2015 Jun; 56(6):839-46. PubMed ID: 25883126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma.
    Eisenhofer G; Pacak K; Huynh TT; Qin N; Bratslavsky G; Linehan WM; Mannelli M; Friberg P; Grebe SK; Timmers HJ; Bornstein SR; Lenders JW
    Endocr Relat Cancer; 2011 Feb; 18(1):97-111. PubMed ID: 21051559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2.
    Eisenhofer G; Lenders JW; Linehan WM; Walther MM; Goldstein DS; Keiser HR
    N Engl J Med; 1999 Jun; 340(24):1872-9. PubMed ID: 10369850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential expression of the regulated catecholamine secretory pathway in different hereditary forms of pheochromocytoma.
    Eisenhofer G; Huynh TT; Elkahloun A; Morris JC; Bratslavsky G; Linehan WM; Zhuang Z; Balgley BM; Lee CS; Mannelli M; Lenders JW; Bornstein SR; Pacak K
    Am J Physiol Endocrinol Metab; 2008 Nov; 295(5):E1223-33. PubMed ID: 18854424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome.
    Eisenhofer G; Huynh TT; Pacak K; Brouwers FM; Walther MM; Linehan WM; Munson PJ; Mannelli M; Goldstein DS; Elkahloun AG
    Endocr Relat Cancer; 2004 Dec; 11(4):897-911. PubMed ID: 15613462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcriptional regulation of phenylethanolamine N-methyltransferase in pheochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2.
    Huynh TT; Pacak K; Wong DL; Linehan WM; Goldstein DS; Elkahloun AG; Munson PJ; Eisenhofer G
    Ann N Y Acad Sci; 2006 Aug; 1073():241-52. PubMed ID: 17102092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pheochromocytoma in von hippel-lindau disease: distinct histopathologic phenotype compared to pheochromocytoma in multiple endocrine neoplasia type 2.
    Koch CA; Mauro D; Walther MM; Linehan WM; Vortmeyer AO; Jaffe R; Pacak K; Chrousos GP; Zhuang Z; Lubensky IA
    Endocr Pathol; 2002; 13(1):17-27. PubMed ID: 12114747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bilateral phaeochromocytomas in von Hippel-Lindau disease: diagnosis by adrenal vein sampling and catecholamine assay.
    Chew SL; Dacie JE; Reznek RH; Newbould EC; Sheaves R; Trainer PJ; Lowe DG; Shand WS; Hungerford J; Besser GM
    Q J Med; 1994 Jan; 87(1):49-54. PubMed ID: 8140217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential expression of erythropoietin and its receptor in von hippel-lindau-associated and multiple endocrine neoplasia type 2-associated pheochromocytomas.
    Vogel TW; Brouwers FM; Lubensky IA; Vortmeyer AO; Weil RJ; Walther MM; Oldfield EH; Linehan WM; Pacak K; Zhuang Z
    J Clin Endocrinol Metab; 2005 Jun; 90(6):3747-51. PubMed ID: 15769989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contrasting clinical manifestations of SDHB and VHL associated chromaffin tumours.
    Srirangalingam U; Khoo B; Walker L; MacDonald F; Skelly RH; George E; Spooner D; Johnston LB; Monson JP; Grossman AB; Drake WM; Akker SA; Pollard PJ; Plowman N; Avril N; Berney DM; Burrin JM; Reznek RH; Kumar VK; Maher ER; Chew SL
    Endocr Relat Cancer; 2009 Jun; 16(2):515-25. PubMed ID: 19208735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perioperative outcomes of syndromic paraganglioma and pheochromocytoma resection in patients with von Hippel-Lindau disease, multiple endocrine neoplasia type 2, or neurofibromatosis type 1.
    Butz JJ; Yan Q; McKenzie TJ; Weingarten TN; Cavalcante AN; Bancos I; Young WF; Schroeder DR; Martin DP; Sprung J
    Surgery; 2017 Dec; 162(6):1259-1269. PubMed ID: 28919049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and biochemical features of sporadic and hereditary phaeochromocytomas: an analysis of 41 cases investigated in a single endocrine centre.
    Patócs A; Karádi E; Tóth M; Varga I; Szücs N; Balogh K; Majnik J; Gláz E; Rácz K
    Eur J Cancer Prev; 2004 Oct; 13(5):403-9. PubMed ID: 15452453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic predisposition to phaeochromocytoma: analysis of candidate genes GDNF, RET and VHL.
    Woodward ER; Eng C; McMahon R; Voutilainen R; Affara NA; Ponder BA; Maher ER
    Hum Mol Genet; 1997 Jul; 6(7):1051-6. PubMed ID: 9215674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phaeochromocytoma in children.
    Yeung LP; Kwan EY; Cheung PT; Low LC
    Hong Kong Med J; 2002 Dec; 8(6):452-5. PubMed ID: 12459603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age at diagnosis of pheochromocytoma differs according to catecholamine phenotype and tumor location.
    Eisenhofer G; Timmers HJ; Lenders JW; Bornstein SR; Tiebel O; Mannelli M; King KS; Vocke CD; Linehan WM; Bratslavsky G; Pacak K
    J Clin Endocrinol Metab; 2011 Feb; 96(2):375-84. PubMed ID: 21147885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.